- Home
- LXRX vs ITOS Comparison
LXRX vs ITOS Comparison
Compare LXRX & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- ITOS
- Stock Information
- Founded
- LXRX 1995
- ITOS 2011
- Country
- LXRX United States
- ITOS United States
- Employees
- LXRX N/A
- ITOS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXRX Health Care
- ITOS Health Care
- Exchange
- LXRX Nasdaq
- ITOS Nasdaq
- Market Cap
- LXRX 124.4M
- ITOS 270.7M
- IPO Year
- LXRX 2000
- ITOS 2020
- Fundamental
- Price
- LXRX $0.36
- ITOS $7.19
- Analyst Decision
- LXRX Buy
- ITOS Strong Buy
- Analyst Count
- LXRX 4
- ITOS 3
- Target Price
- LXRX $3.67
- ITOS $26.00
- AVG Volume (30 Days)
- LXRX 9.5M
- ITOS 334.2K
- Earning Date
- LXRX 03-06-2025
- ITOS 03-05-2025
- Dividend Yield
- LXRX N/A
- ITOS N/A
- EPS Growth
- LXRX N/A
- ITOS N/A
- EPS
- LXRX N/A
- ITOS N/A
- Revenue
- LXRX $31,081,000.00
- ITOS $35,000,000.00
- Revenue This Year
- LXRX N/A
- ITOS N/A
- Revenue Next Year
- LXRX $101.91
- ITOS $121.70
- P/E Ratio
- LXRX N/A
- ITOS N/A
- Revenue Growth
- LXRX 2481.48
- ITOS 177.89
- 52 Week Low
- LXRX $0.28
- ITOS $6.67
- 52 Week High
- LXRX $2.62
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- LXRX 32.86
- ITOS 48.18
- Support Level
- LXRX $0.33
- ITOS $6.73
- Resistance Level
- LXRX $0.41
- ITOS $7.32
- Average True Range (ATR)
- LXRX 0.06
- ITOS 0.38
- MACD
- LXRX -0.02
- ITOS 0.03
- Stochastic Oscillator
- LXRX 16.38
- ITOS 53.06
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.